Pharming Group (NASDAQ:PHAR) Upgraded to “Strong-Buy” at Wall Street Zen

Pharming Group (NASDAQ:PHAR) was upgraded by equities researchers at Wall Street Zen to a “strong-buy” rating in a report issued on Saturday.

A number of other equities research analysts also recently issued reports on the stock. Zacks Research raised shares of Pharming Group from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pharming Group in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Pharming Group currently has an average rating of “Buy” and an average price target of $38.00.

Pharming Group Price Performance

NASDAQ:PHAR opened at $17.80 on Friday. Pharming Group has a 52 week low of $7.50 and a 52 week high of $18.30. The stock’s fifty day moving average is $15.96 and its two-hundred day moving average is $13.72. The company has a market capitalization of $1.22 billion and a P/E ratio of -1,778.22. The company has a quick ratio of 2.39, a current ratio of 3.16 and a debt-to-equity ratio of 0.35.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.05. The firm had revenue of $97.30 million during the quarter, compared to the consensus estimate of $98.22 million. Pharming Group had a return on equity of 0.46% and a net margin of 0.30%. Equities analysts expect that Pharming Group will post -0.2 EPS for the current year.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC purchased a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 2,979 shares of the company’s stock, valued at approximately $32,000. 0.03% of the stock is owned by institutional investors and hedge funds.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.